March 15, 2025

Continence Care

Finance

Coloplast A/S – Interim Financial Report, 9M 2023/24

Coloplast A/S 9M 2023/24Interim financial results, 9M 2023/241 October 2023 – 30 June 2024 Coloplast delivered 8% organic growth and an EBIT margin1) of 27% in Q3, with 11% growth in absolute EBIT1). Reported revenue in DKK grew 13% which includes 4%-points contribution from Kerecis (underlying growth of around 35%). Organic growth rates by business

Read More
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent. View more
Accept
Decline